Clinical trial · Observational
Sample Collection Study in Patients With Suspected Melanoma Utilizing DermTech's Non-invasive Adhesive Patch Biopsy Kits
A Multi-center Sample Collection Study in Patients With Suspected Melanoma Utilizing DermTech's Non-invasive Adhesive Patch Biopsy Kits
NCT04550000CI-TRIAL-00061800completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A multi-center sample collection study in patients presenting with pigmented lesion(s) suspicious for melanoma. All suspicious lesions should meet at least one of the "ABCDE" criteria.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Up to 1000 samples will be compared for gene expression analysis results compared to biopsy findings.
- timeFrame
- Samples will be extracted and analyzed once up to 1000 samples have been collected and compared to surgical biopsy reports. Analysis results are expected in 2021
- description
- gene expression associated with melanoma vs non-melanoma compared to surgical biopsy
- measure
- Up to 1000 samples will be compared to biopsy results for DNA mutations
- timeFrame
- Samples will be extracted and analyzed once up to 1000 samples have been collected and compared to surgical reports and DNA mutation analysis. Analysis results are expected in 2021
- description
- Dna mutations associated with more aggressive forms of melanoma
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 21 Years
Show eligibility criteria text
Inclusion Criteria: 1. Males and females at least 21 years of age 2. Have a pigmented lesion suspicious for melanoma the pigmented lesion meets at least one of the "ABCDE" criteria 3. The pigmented lesion mst be at least 3mm and not more than 16mm in diameter 4. Patient is willing to follow the start of care to test and treat the pigmented lesion as determined by the treating physician 5. Willing to have DermTech adhesive patch biopsies performed 6. Must be able to complete study procedures as required by the protocol 7. Willing to provide informed consent to participate in this trial Exclusion Criteria: 1. Require a surgical biopsy or excision of the lesion of interest prior to the DermTech non-invasive patch biopsy(ies) 2. Has an ulcerated or bleeding lesion that could confound the biopsy results 3. Has a suspicious lesion(s) in an area that was previously surgically biopsied 4. Has a lesion that is classified as "clinically" evident melanoma appropriate for excision 5. The lesion to be sampled is on the mucosal surface, palmoplantar surface or other area where adhesive patch biopsies cannot be performed 6. Has a known sensitivity to adhesive patches 7. Any significant medical condition that would indicate an unreasonable risk to the patient or potential interference with the study 8. Lesion is in a location were sufficient removal of non-vellus hair cannot be achieved (e.g., scalp) 9. Suspected non-melanoma skin cancer 10. Patients with contraindication(s) to surgical biopsy -
References
Publications (2)
- RESULTYao Z, Allen T, Oakley M, Samons C, Garrison D, Jansen B. Analytical Characteristics of a Noninvasive Gene Expression Assay for Pigmented Skin Lesions. Assay Drug Dev Technol. 2016 Aug;14(6):355-63. doi: 10.1089/adt.2016.724. PMID 27505074
- RESULTGerami P, Yao Z, Polsky D, Jansen B, Busam K, Ho J, Martini M, Ferris LK. Development and validation of a noninvasive 2-gene molecular assay for cutaneous melanoma. J Am Acad Dermatol. 2017 Jan;76(1):114-120.e2. doi: 10.1016/j.jaad.2016.07.038. Epub 2016 Oct 1. PMID 27707590